Targeting Interleukin-6 Helps to Mitigate the Side Effects of Immunotherapy

Researchers at The University of Texas MD Anderson Cancer Center have identified a new strategy to reduce immune-related adverse events by targeting immunotherapy with the cytokine interleukin-6 (IL-6). The study, published in Cancer Cell, provides evidence for the concept of combining immune checkpoint blockers and cytokine blockers to selectively inhibit inflammatory autoimmune responses.   While immunotherapy in combination with anti-pd...

Article